Doxorubicin Market Revenue, Driving Factors, Key Players, Strategies, Trends, Forecast Till 2030

Comments · 121 Views

The Doxorubicin Market is projected to reach USD 1383.75 Million by 2030 at 6.20% CAGR during the forecast period 2022-2030.

The Doxorubicin Market is projected to reach USD 1383.75 Million by 2030 at 6.20% CAGR during the forecast period 2022-2030.

Doxorubicin is a type of chemotherapy medicine called an anthracycline. It is used to reduce or diminish the growth of cancer cells by blocking an enzyme called topo isomerase. Factors that are propelling the growth of the doxorubicin market are surge in geriatric population, rising prevalence of different types of cancer, increasing awareness for cancer treatment. According to the International Federation of Pharmaceutical Manufacturers Associations, global pharmaceutical industry has spent more than USD 149.8 billion on pharmaceutical Research and development activities.

The various side effects, cost containment policies by various governments, stringent regulatory environment for product approval, are likely to hinder market growth during the forecast period.

Regional Analysis

The American market is expected to dominate the global doxorubicin market during the forecast period due to the presence of major manufacturers, increase in number of cancer cases, awareness for the treatment of cancer, and favorable reimbursement and regulatory authorities. The European market is expected to be the second-largest due to growing pool of cancer patients and rising healthcare expenditure. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing geriatric population in countries such as India and China, increasing awareness programs for the treatment of cancer, government initiatives and investment for the development of healthcare sector and increasing number manufacturers finding opportunities in developing countries. The market in the Middle East Africa is likely to account for the smallest share of the global doxorubicin market.

Segmentation

The global doxorubicin market research has been segmented on the basis of application, and distribution channel.

The application segment is divided into liver cancer, gastric cancer, doxorubicin breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.

The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.

Key Players

Some of the key players in the global Doxorubicin market are Doxorubicin market are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK PHARMACEUTICALS LTD. and various others

Browse Complete Report @ https://www.marketresearchfuture.com/reports/doxorubicin-market-7376

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

 

Comments
contentstudio